The Changing Site Landscape: Networks, Academic Centers, and Independent Sites
Published October 2026 — Tufts CSDD findings reported in October 2026 show network-affiliated sites growing from 1.3% of sites in 2006 to 6.7% in 2025 and conducting 10.4% of active FDA-regulated trials, while the share of independent sites has declined.
Site Networks Are a Small but Growing Share
The investigative site market has been consolidating for years, but reliable data on its structure have been scarce. A Tufts Center for the Study of Drug Development study, conducted with a working group of 10 sponsor and CRO companies and reported in Clinical Leader in October 2026, provides the most detailed recent picture.
The study combined a global survey, fielded from late February through early April 2025 and drawing 1,154 responses from an estimated 1,090 unique sites, with FDA investigator data used to estimate trial volume by site type. This brief summarizes what it shows about academic medical centers, independent sites, and site networks.
Key Findings
Network-affiliated sites made up 6.7% of sites in 2025, up from 1.3% in 2006, and conducted 10.4% of active global FDA-regulated trials.
Independent and part-time sites fell from 52.8% of sites in 2019 to 45.2% in 2025. They conducted 35.8% of trials.
AMC-affiliated sites accounted for 48.1% of sites and 53.8% of active global FDA-regulated trials.
Network sites averaged 20.4 trials per year, compared with 27.3 at AMC sites and 15.2 at independent and part-time sites.
How the Segments Differ
Beyond market share, the study describes how the three site types are staffed and what they find difficult.
Staffing Levels
AMC sites reported an average of 43.1 clinical staff, independent and part-time sites 23.9, and network sites 22.0. Network sites therefore run a comparatively high number of trials with a smaller clinical team.
Staff Experience
The share of clinical staff with more than six years of experience was 59.0% at independent and part-time sites, 57.1% at AMCs, and 44.0% at network sites. Networks employ a less experienced clinical workforce on average.
Shared Challenges
Across all segments the top operating challenges were participant enrollment, protocol complexity, and staff turnover.
Challenges Specific to Networks
Among network sites, 22.1% cited pressure to make a profit. Communicating and collaborating with CROs was cited by 19.5% of network sites and 17.2% of independent and part-time sites.
Therapeutic Focus
Network sites were concentrated in cardiovascular and metabolic disease, dermatology, and respiratory disease. Vaccine trials were run by 61.0% of network sites and 15.3% of AMC sites.
Implications for Sites and Sponsors
The data describe both the appeal of the network model and the points where it needs care.
Network sites conduct a share of trials larger than their share of sites. For sponsors, they offer concentrated capacity in common therapeutic areas.
A younger clinical workforce makes training, standard procedures, and oversight more important in networks than elsewhere. Governance is how a network compensates.
Independent and part-time sites still conduct more than a third of trials. Models that let them keep their independence while sharing infrastructure address the pressures behind their decline.
Conclusions
The site landscape is shifting gradually toward networks and academic centers and away from stand-alone independent sites. Networks remain a small share of all sites but conduct a disproportionate share of trials.
The study also reported sponsor-supplied performance data for a subset of sites, which the authors describe as a small sample needing further research; those figures are not summarized here. The structural findings are the more robust part of the work, and they support the case for network models built on governance and staff development.
This brief summarizes published industry research. Figures are reported as stated in the sources below and have not been independently verified by Clinitiative.
Discuss These Findings with Our Team
Talk with us about what this research means for your protocol, site selection, or enrollment plan.